Latest News

Vesalius Biocapital III Fund closes at €120 million

© fotolia.com/sdecoret


by TG

Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.

The fund includes commitments of €30m from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. Vesalius Biocapital III has already executed three investments. These include investments in Forendo, a clinical stage drug development company focusing on novel treatments in women’s health; Mecuris, a Munich-based medtech developing an easy-to-use online platform for customizable and 3D-printed orthotics and prosthetics; and SWORD Health, a tech-enabled provider of physical therapy, pairing its AI-powered digital therapists with human clinical teams to recover patients faster and better.

Vesalius Biocapital III targets later-stage European life science companies in drug development, medtech, diagnostics and digital health with the goal of investing in 10 to 15 companies over the lifetime of the fund.

Cellink AB acquires Ginolis Oy for €70m

Under the agreement, Cellink AB is set to acquire all shares for a purchase price on cash- and debt-free basis of €70m. Forty per cent of the...

Avantium NV bags money for demo plant

The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January. FDCA is the key building block for...

Angelini Pharma to take over Arvelle Therapeutics

Under the terms of the agreement, Angelini Pharma will acquire Arvelle Therapeutics in an all-cash transaction for a total consideration of up to...

Immunocore bags US$75m in Series C round

The round included support from existing investors and funds and accounts managed by BlackRock. Immunocore said it will use the proceeds to ...

EMA greenlights BioNtech's COVID-19 vaccine

It's the first time, that the European Medicines Agency (EMA) has recommended a mRNA vaccine. On Monday,  the drug agency cleared the way for...

Drug set to rescue COVID-19 patients at ICUs

Initial data from an US expanded access  (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...

Biomarker identifies high-risk COVID-19 patients

The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...